In the other world, having access to IFN, most newly diagnosed patients with ET, PV, and hyperproliferative myelofibrosis are treated routinely with low-dose IFN as described in several studies and reviews during recent years [96–103]. This evidence concerns the gene IFNA1 and myelofibrosis.